CL2008000445A1 - Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un - Google Patents

Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un

Info

Publication number
CL2008000445A1
CL2008000445A1 CL200800445A CL2008000445A CL2008000445A1 CL 2008000445 A1 CL2008000445 A1 CL 2008000445A1 CL 200800445 A CL200800445 A CL 200800445A CL 2008000445 A CL2008000445 A CL 2008000445A CL 2008000445 A1 CL2008000445 A1 CL 2008000445A1
Authority
CL
Chile
Prior art keywords
pcv2
antigen
animal
profilaxis
prophylaxis
Prior art date
Application number
CL200800445A
Other languages
English (en)
Spanish (es)
Inventor
Vicky Elbers Knut Ki Fachinger
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38191300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000445(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of CL2008000445A1 publication Critical patent/CL2008000445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL200800445A 2007-02-13 2008-02-12 Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un CL2008000445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20070102250 EP1958644A1 (en) 2007-02-13 2007-02-13 Prevention and treatment of sub-clinical pcvd

Publications (1)

Publication Number Publication Date
CL2008000445A1 true CL2008000445A1 (es) 2008-07-04

Family

ID=38191300

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800445A CL2008000445A1 (es) 2007-02-13 2008-02-12 Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un

Country Status (23)

Country Link
US (5) US7943298B2 (enExample)
EP (3) EP1958644A1 (enExample)
JP (1) JP5562041B2 (enExample)
KR (1) KR101521465B1 (enExample)
CN (1) CN101610786B (enExample)
AR (1) AR065319A1 (enExample)
AU (1) AU2008214639B2 (enExample)
BR (1) BRPI0807493A2 (enExample)
CA (1) CA2676568C (enExample)
CL (1) CL2008000445A1 (enExample)
CY (1) CY1114577T1 (enExample)
DK (2) DK2481421T3 (enExample)
ES (2) ES2434117T3 (enExample)
MX (1) MX2009008577A (enExample)
MY (1) MY152149A (enExample)
PL (1) PL2114447T3 (enExample)
PT (1) PT2114447E (enExample)
RU (1) RU2520759C2 (enExample)
SI (1) SI2114447T1 (enExample)
TW (1) TWI438003B (enExample)
UA (1) UA100507C2 (enExample)
WO (1) WO2008098909A1 (enExample)
ZA (1) ZA200904806B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP1976558B1 (en) 2005-12-29 2017-03-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 immunogenic composition for lessening clinical symptoms in pigs
HUE054868T2 (hu) 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2726777T3 (es) 2006-12-15 2019-10-09 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina anti-PCV2 en dosis única
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009126356A2 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
EP2353610A4 (en) * 2008-11-19 2013-12-11 Avi Mex S A De C V Lab RECOMBINANT INACTIVATED VIRUS VECTOR VACCINE
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
AU2010357208A1 (en) * 2010-07-08 2013-02-21 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
US20140348874A1 (en) * 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
EP3052516B1 (en) 2013-10-02 2020-01-01 Boehringer Ingelheim Animal Health USA Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
ES2771899T3 (es) * 2013-12-03 2020-07-07 Intervet Int Bv Vacuna contra circovirus porcino de tipo 2
JP6629975B2 (ja) * 2015-12-28 2020-01-15 アグリカルチュラル テクノロジー リサーチ インスティテュート ブタシルコウイルス２型キャプシドタンパク質の調製方法及びそれを含む医薬組成物

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE3875762T2 (de) * 1987-03-17 1993-05-13 Akzo Nv Adjuvanzienmischung.
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
AU638970B2 (en) 1989-01-23 1993-07-15 Auspharm International Limited Vaccine composition
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5202430A (en) 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
WO1991018627A1 (en) 1990-05-29 1991-12-12 Smithkline Beecham Corporation Swine pneumonia vaccine and method for the preparation thereof
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
DK0555366T3 (da) 1990-11-01 2000-08-28 Univ Iowa State Res Found Inc Fremgangsmåde til bakteriel svækkelse og vaccine
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
CA2076744C (en) 1991-08-26 2000-06-27 Danny W. Chladek Viral agent associated with mystery swine disease
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
PT1820512E (pt) 1994-05-10 2013-10-09 Boehringer Ingelheim Vetmed Vacina viva modificada melhorada contra brsv
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
AU4070597A (en) 1996-08-16 1998-03-06 The Texas A & M University System Modifying insect cell gylcosylation pathways with baculovirus expression vectors
DK0835930T3 (da) 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US20060029617A1 (en) 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
DE07008633T1 (de) 1997-12-11 2008-12-18 Merial Virus des multisystemischen Kümmersyndroms bei Absatzferkeln
EP1064024A4 (en) 1998-03-13 2005-04-06 Univ Georgia Res Found VACCINES AGAINST CIRCOVIRUS INFECTIONS
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
WO2000031275A1 (en) 1998-11-19 2000-06-02 Azwell Inc. Recombinant lysophosphatidic acid phosphatase
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6656478B1 (en) 1999-11-12 2003-12-02 Samuel D. Charles Cross-protective salmonella vaccines
JP2003518073A (ja) 1999-12-21 2003-06-03 メリアル クリプトスポリジウムパルヴァムと他の腸内病原体の抗原を含む組成物およびワクチン
AU2001266940A1 (en) 2000-06-15 2001-12-24 Purdue Research Foundation Vaccine for congenital tremors in pigs
US6808900B2 (en) 2000-06-15 2004-10-26 Manitoba, University Of Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
PT1303265E (pt) 2000-07-20 2007-10-09 Lauras As ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja) 2001-02-23 2002-09-03 Nippon Biologicals Inc マレック病ワクチンおよびその製造方法
JP4038127B2 (ja) 2001-03-27 2008-01-23 ユニバーシティ オブ サスカチュワン サーコウイルスの培養方法
US20030096377A1 (en) 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
CN101524532B (zh) 2001-07-02 2014-03-19 硕腾P有限责任公司 单剂量猪肺炎支原体疫苗
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
AU2003220240A1 (en) 2002-03-13 2003-09-29 Biophysica, Inc. Boswellin compositions enhanced with 3-beta-acety1-11-keto-beta-boswellic acid (akba), industrial manufacture and their uses
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7223207B1 (en) 2002-09-13 2007-05-29 Simon Basyuk Exercise and massage device
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
US7408636B2 (en) 2002-10-31 2008-08-05 Chemimage Corporation Method and apparatus for dark field chemical imaging
AU2004209985B2 (en) 2003-02-03 2008-09-18 Cerebus Biologicals, Inc. Methods for treating, preventing and detecting Helicobacter infection
US7563449B2 (en) 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
CN1458167A (zh) 2003-06-02 2003-11-26 中国农业科学院哈尔滨兽医研究所 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
CA2533581C (en) 2003-07-24 2012-05-08 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
RU2420570C2 (ru) 2003-07-25 2011-06-10 Бёрингер Ингельхайм Ветмедика, Инк. Lawsonia intracellularis ЕВРОПЕЙСКОГО ПРОИСХОЖДЕНИЯ И ВАКЦИНЫ, ДИАГНОСТИЧЕСКИЕ АГЕНТЫ НА ЕЕ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
FR2861731B1 (fr) 2003-10-30 2006-02-24 Centre Nat Rech Scient Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
WO2005112995A1 (en) 2004-04-26 2005-12-01 Choongang Vaccine Laboratory Co., Ltd. Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
CN1579553A (zh) 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
KR100478845B1 (ko) 2004-06-22 2005-03-24 채찬희 돼지 이유자돈 전신성 소모성 증후군 예방 및 치료용 생물학적 조성물
AU2005319716A1 (en) 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
JP2008526921A (ja) 2005-01-13 2008-07-24 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 改善されたｐｒｒｓワクチン
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP1869471B1 (en) 2005-04-13 2016-06-08 Merial, Inc. Method for porcine circovirus production
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2620727C (en) 2005-09-09 2015-06-16 Intervet International B.V. Porcine circovirus type 2 vaccine
HUE054868T2 (hu) 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
EP1976558B1 (en) 2005-12-29 2017-03-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 immunogenic composition for lessening clinical symptoms in pigs
US20100136060A1 (en) 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2726777T3 (es) 2006-12-15 2019-10-09 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina anti-PCV2 en dosis única
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
GB0712160D0 (en) 2007-06-22 2007-08-01 Univ Ghent Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009126356A2 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US20110033495A1 (en) 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
US20100150959A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
US20110150770A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
RS59952B1 (sr) 2010-03-16 2020-03-31 Virginia Tech Intellectual Properties Inc Živa atenuisana vakcina protiv himernog svinjskog cirkovirusa
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
CN103122352B (zh) 2012-09-27 2015-02-11 华中农业大学 一种猪圆环病毒2型重组杆状病毒及制备方法和应用
DK2961766T3 (da) 2013-03-01 2019-07-15 Boehringer Ingelheim Animal Health Usa Inc Kvantificering af vaccinesammensætninger
CN105246505A (zh) 2013-04-30 2016-01-13 勃林格殷格翰动物保健公司 PCV2a亚型(PCV2a)的ORF2蛋白用于交叉保护中的用途
US20140348874A1 (en) 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
HUE060972T2 (hu) 2013-08-23 2023-05-28 Boehringer Ingelheim Animal Health Usa Inc 2-es típusú sertés cirkovírus (PCV) alegység vakcina
EP3052516B1 (en) 2013-10-02 2020-01-01 Boehringer Ingelheim Animal Health USA Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
WO2016160761A2 (en) 2015-03-30 2016-10-06 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 carrier platform

Also Published As

Publication number Publication date
AR065319A1 (es) 2009-05-27
EP2114447A1 (en) 2009-11-11
BRPI0807493A2 (pt) 2014-05-27
US7943298B2 (en) 2011-05-17
MX2009008577A (es) 2009-08-21
ES2434117T3 (es) 2013-12-13
US20110182935A1 (en) 2011-07-28
CN101610786B (zh) 2012-10-10
US20170087241A1 (en) 2017-03-30
KR101521465B1 (ko) 2015-05-19
US20130273099A1 (en) 2013-10-17
CA2676568C (en) 2019-03-19
EP1958644A1 (en) 2008-08-20
JP5562041B2 (ja) 2014-07-30
JP2011511754A (ja) 2011-04-14
US9132187B2 (en) 2015-09-15
CA2676568A1 (en) 2008-08-21
RU2009134222A (ru) 2011-03-20
US9943587B2 (en) 2018-04-17
DK2114447T3 (da) 2013-10-28
US20150343052A1 (en) 2015-12-03
MY152149A (en) 2014-08-15
EP2481421B1 (en) 2015-09-23
EP2481421A1 (en) 2012-08-01
US9555092B2 (en) 2017-01-31
CN101610786A (zh) 2009-12-23
TW200902057A (en) 2009-01-16
PT2114447E (pt) 2013-10-10
WO2008098909A1 (en) 2008-08-21
CY1114577T1 (el) 2016-10-05
US20090010954A1 (en) 2009-01-08
DK2481421T3 (en) 2016-01-04
EP2114447B1 (en) 2013-08-07
UA100507C2 (ru) 2013-01-10
RU2520759C2 (ru) 2014-06-27
ZA200904806B (en) 2013-09-25
ES2555132T3 (es) 2015-12-29
KR20090109584A (ko) 2009-10-20
PL2114447T3 (pl) 2014-01-31
US8496940B2 (en) 2013-07-30
SI2114447T1 (sl) 2013-11-29
AU2008214639A1 (en) 2008-08-21
TWI438003B (zh) 2014-05-21
AU2008214639B2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CL2008000445A1 (es) Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un
CL2008000008A1 (es) Uso de un antigeno de circovirus porcino de tipo 2 (pcv2) para la profilaxis y tratamiento del complejo respiratorio porcino (prdc) y/o cualquier signo clinico asociado con prdc en un animal.
CL2014002087A1 (es) Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal.
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
DOP2012000150A (es) Triazolopiridinas
BR112014004515A2 (pt) "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende"
UY36422A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
CL2007003648A1 (es) Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
AR068363A1 (es) Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
ECSP13013011A (es) Triazolopiridinas
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ECSP14004812A (es) Triazolopiridinas sustituidas
ECSP12012338A (es) Triazolopiridinas sustituidas
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
AR090569A1 (es) Agregados de nanoparticulas que contienen osteopontina y particulas que contienen calcio y/o estroncio
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
MX336204B (es) Una composicion y uso de la misma en el tratamiento de ragades anales.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2